How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,190 results for

Benign Prostatic Hyperplasia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Treatment Preferences of Patients With Benign Prostatic Hyperplasia Before and After Using a Web-based Decision Aid. (Abstract)

Treatment Preferences of Patients With Benign Prostatic Hyperplasia Before and After Using a Web-based Decision Aid. To evaluate treatment preferences of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) before and after using a web-based decision aid (DA).Between July 2016 and January 2017 patients were invited to use a web-based LUTS/BPH DA. Treatment preferences (for lifestyle advices, medication or surgery) before and after DA use and responses

2020 Urology

82. Optimal high-density lipoprotein cholesterol level for decreasing benign prostatic hyperplasia in men not taking statin medication: A historical cohort study. (Abstract)

Optimal high-density lipoprotein cholesterol level for decreasing benign prostatic hyperplasia in men not taking statin medication: A historical cohort study. We evaluated the optimal high-density lipoprotein cholesterol level for benign prostatic hyperplasia (BPH) prevention in men not taking statin medication using a large historical cohort.We initially selected 130 454 men who underwent health checkups in 2009 from the National Health Information Database of the National Health Insurance

2020 Prostate

83. Characterizing the Benign Prostatic Hyperplasia Literature: A Bibliometric Analysis. (Abstract)

Characterizing the Benign Prostatic Hyperplasia Literature: A Bibliometric Analysis. To characterize the current landscape and future directions of academic benign prostatic hyperplasia (BPH) by using bibliometric analysis.We used the Web of Science Core Collection to conduct a bibliometric analysis of leading BPH articles. Bibliometric analyses are quantitative approaches examining the impact of academic literature. We used the following search terms and Boolean logic "("benign prostat (...) *") AND (hyperplasia OR enlarg*)" and characterized the 100 most-cited BPH articles through 2018 including citations, journal, author, year, and country.The top 100 BPH articles were published between 1978 and 2012. Citations ranged from 153 to 2171 across 27 different journals, including 10 urology-specific journals. The Journal of Urology was the most published journal (n = 25), followed by European Urology (n = 17), and Urology (n = 15). In general, the oldest 10 articles focused on BPH etiology/pathogenesis

2020 Urology

84. Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review

Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review Brasure M, MacDonald R, Dahm P, Olson CM, Nelson VA, Fink HA, Risk M, Rwabasonga B, Wilt TJ Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Brasure M, MacDonald R, Dahm P, Olson CM, Nelson VA, Fink HA, Risk M, Rwabasonga B, Wilt TJ. Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 178. 2016 Authors' objectives To assess the efficacy, comparative effectiveness, and adverse

2016 Health Technology Assessment (HTA) Database.

85. Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) (TA273)

Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) (TA273) Overview | Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) | Guidance | NICE Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) Technology appraisal [TA273] Published date: 23 January 2013 Share Guidance NICE is unable to recommend the use in the NHS of tadalafil (...) for the treatment of symptoms associated with benign prostatic hyperplasia because no evidence submission was received from the manufacturer of the technology. Explore © NICE [year]. All rights reserved. Subject to .

2013 National Institute for Health and Clinical Excellence - Technology Appraisals

86. [A comparative analysis of the effectiveness of serenoa repens and serenoa repens in combination with urtica dioiccus for lower urinary symptoms suggestive of benign prostatic hyperplasia associated with chronic inflammation in prostate tissue]. (Abstract)

[A comparative analysis of the effectiveness of serenoa repens and serenoa repens in combination with urtica dioiccus for lower urinary symptoms suggestive of benign prostatic hyperplasia associated with chronic inflammation in prostate tissue]. Benign prostatic hyperplasia (BPH) is the most common proliferative disease of the prostate gland in the elderly.The results of an open, randomized comparative study of the effectiveness of Serenoa repens in the combination with Urtica dioiccus (...) , an increase in Qmax, a decrease in postvoid residual urine volume and an intensity of the inflammatory process in the prostatic tissue. However, in patients with BPH associated with chronic inflammation, it is preferable to use Serenoa repens in combination with Urtica dioiccus.

2019 Urologii︠a︡ (Moscow, Russia : 1999) Controlled trial quality: uncertain

87. Editorial Comment on: 1470 nm Diode Laser Enucleation vs Plasmakinetic Bipolar Resection of the Prostate for Benign Prostatic Hyperplasia: A Randomized Study by Zhang et al. (From: Zhang J, Wang X, Zhang Y, et al. J Endourol 2019;33:211-217; DOI: 10.108 (Abstract)

Editorial Comment on: 1470 nm Diode Laser Enucleation vs Plasmakinetic Bipolar Resection of the Prostate for Benign Prostatic Hyperplasia: A Randomized Study by Zhang et al. (From: Zhang J, Wang X, Zhang Y, et al. J Endourol 2019;33:211-217; DOI: 10.108 30572717 2019 11 20 1557-900X 33 3 2019 Mar Journal of endourology J. Endourol. Editorial Comment on: 1470 nm Diode Laser Enucleation vs Plasmakinetic Bipolar Resection of the Prostate for Benign Prostatic Hyperplasia: A Randomized Study

2019 Journal of Endourology Controlled trial quality: uncertain

88. Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150cc): 1-year Results. (Full text)

Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150cc): 1-year Results. To report 12-month safety and effectiveness outcomes of the Aquablation procedure for the treatment of men with symptomatic BPH and large-volume prostates.101 men with moderate-to-severe BPH symptoms and prostate volumes of 80-150cc underwent a robotic-assisted Aquablation procedure in a prospective multicenter international clinical trial. Functional and safety outcomes were assessed at 12 months (...) postoperatively.Mean prostate volume was 107cc (range 80-150). Mean operative time was 37 minutes and mean Aquablation resection time was 8 minutes. The average length of hospital stay following the procedure was 1.6 days. Mean IPSS improved from 23.2 at baseline to 6.2 at 12 months (p<.0001). Mean IPSS quality of life improved from 4.6 at baseline to 1.3 at 12-month follow-up (p<.0001). Significant improvements were seen in Qmax (12-month improvement of 12.5 cc/sec) and post-void residual (drop of 171 cc in those

2019 Urology PubMed abstract

89. E-cadherin is downregulated in benign prostatic hyperplasia and required for tight junction formation and permeability barrier in the prostatic epithelial cell monolayer. (Abstract)

E-cadherin is downregulated in benign prostatic hyperplasia and required for tight junction formation and permeability barrier in the prostatic epithelial cell monolayer. We previously reported the presence of prostate-specific antigen (PSA) in the stromal compartment of benign prostatic hyperplasia (BPH). Since PSA is expressed exclusively by prostatic luminal epithelial cells, PSA in the BPH stroma suggests increased tissue permeability and the compromise of epithelial barrier integrity. E (...) . In vitro cell line studies using benign prostatic epithelial cell lines were performed to determine the impact of small interfering RNA knockdown of E-cadherin on transepithelial electrical resistance and diffusion of fluorescein isothiocyanate (FITC)-dextran in transwell assays.The number of kiss points in tight junctions was reduced in BPH epithelial cells as compared with the normal adjacent prostate. Immunostaining confirmed E-cadherin downregulation and revealed a discontinuous E-cadherin staining

2019 Prostate

90. Factors influencing intraoperative blood loss in patients undergoing Holmium Laser Enucleation of the Prostate (HoLEP) for Benign Prostatic Hyperplasia: a large multicenter analysis. (Abstract)

Factors influencing intraoperative blood loss in patients undergoing Holmium Laser Enucleation of the Prostate (HoLEP) for Benign Prostatic Hyperplasia: a large multicenter analysis. To assess blood loss during holmium laser enucleation of the prostate (HoLEP) and investigate the factors influencing it.analysis of patients with benign prostatic hyperplasia (BPH) treated with HoLEP at three centres. Haemoglobin and haematocrit were measured before surgery and hospital discharge. All blood (...) transfusions performed during and after HoLEP were recorded. Blood loss outcomes were analysed regarding antithrombotic (antiplatelet/anticoagulant) therapies and drug treatments for BPH and other conditions.The analysis included 963 patients with a mean age of 72 years. Mean (range) prostate size was 102 (40-316) g; 28% of patients were receiving antiplatelets and 11% anticoagulants. Mean (range) prostate-specific antigen was 6.0 (0.3-43.5) ng/dL. Mean (range) operation time was 77 (28-178) min. Bladder

2019 Urology

91. Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate. (Abstract)

Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate. The benign prostatic syndrome, comprising lower urinary tract symptomatology secondary to benign prostatic hyperplasia/enlargement, represents a major health care issue in westernized countries. The pharmacological management involves alpha-adrenoceptor antagonists, intervention into the hormonal control of prostate growth using inhibitors of the enzyme 5-alpha-reductase (...) /antagonists of endogenous peptides, botulinum toxin, NX-1207), the steroidal axis (cetrorelix) or the metabolic turn-over (lonidamine), as well as the combination of drugs already established in the treatment of lower urinary tract symptomatology/benign prostatic hyperplasia (phosphodiesterase 5 inhibitor plus alpha-adrenoceptor antagonist).Many research efforts have provided the basis for the development of new therapeutic modalities for the management of lower urinary tract dysfunctions, some of which

2019 World journal of urology

92. Effects of poloxamer-based thermo-sensitive sol-gel agent on urethral stricture after transurethral resection of the prostate for benign prostatic hyperplasia: a multicentre, single-blinded, randomised controlled trial. (Full text)

Effects of poloxamer-based thermo-sensitive sol-gel agent on urethral stricture after transurethral resection of the prostate for benign prostatic hyperplasia: a multicentre, single-blinded, randomised controlled trial. To evaluate the effectiveness of poloxamer-based thermo-sensitive sol-gel instillation, after transurethral resection of the prostate (TURP), for preventing urethral stricture.In all, 198 patients underwent TURP for benign prostatic hyperplasia. Recruited patients were randomly (...) divided into two groups: groups A and B. Patients in Group A (100 patients, experimental group) received poloxamer-based thermo-sensitive sol-gel instillation and patients in the Group B (98 patients, control group) received lubricant instillation after TURP. Each patient was evaluated at 4 (V1), 12 (V2), and 24 weeks (V3) after TURP. The effectiveness of poloxamer-based thermo-sensitive sol-gel instillation was evaluated based on the International Prostate Symptom Score (IPSS), IPSS-Quality of Life

2019 BJU international Controlled trial quality: uncertain PubMed abstract

93. WATER vs WATER II: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30cc-80cc and 80cc-150cc Prostates. (Full text)

WATER vs WATER II: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30cc-80cc and 80cc-150cc Prostates. Surgical options, especially those with short learning curves are limited when treating large prostates for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Aquablation (AQUABEAM System, PROCEPT BioRobotics, Inc., USA) could be this novel tool with global reproducibility, independent of prostate volume. We compared the outcomes of Aquablation (...) in 30cc to 80cc prostates with those in 80cc to 150cc.WATER (NCT02505919) is a prospective, double-blind, multicenter, international clinical trial comparing Aquablation and TURP for the treatment of LUTS/BPH in prostates between 30cc and 80cc. WATER II (NCT03123250) is a prospective, multicenter, single-arm international clinical trial of Aquablation in prostates between 80cc and 150cc. We compare baseline parameters and 12-month outcomes in 116 WATER (W-I) and 101 WATER II (W-II) study subjects

2019 BJU international PubMed abstract

94. Prostate artery embolisation for benign prostatic hyperplasia. (Full text)

Prostate artery embolisation for benign prostatic hyperplasia. 29921580 2019 03 12 2019 03 12 1756-1833 361 2018 Jun 19 BMJ (Clinical research ed.) BMJ Prostate artery embolisation for benign prostatic hyperplasia. k2537 10.1136/bmj.k2537 Challacombe Ben B Departments of Urology and Interventional Radiology, Guy's and St Thomas Hospitals NHS Foundation Trust, London SE1 9RT, UK benchallacombe@doctors.org.uk. Sabharwal Tarun T Departments of Urology and Interventional Radiology, Guy's and St (...) Thomas Hospitals NHS Foundation Trust, London SE1 9RT, UK. eng Comparative Study Editorial Multicenter Study Observational Study Randomized Controlled Trial 2018 06 19 England BMJ 8900488 0959-8138 AIM IM Decision Making Embolization, Therapeutic adverse effects methods Humans Lasers, Solid-State therapeutic use Male Prostate blood supply pathology Prostatic Hyperplasia diagnostic imaging therapy Urinary Bladder Neck Obstruction physiopathology Urodynamics Vascular Surgical Procedures methods

2019 BMJ (Clinical research ed.) Controlled trial quality: uncertain PubMed abstract

95. Prostatic Artery Embolization for Benign Prostatic Hyperplasia: Prospective Randomized Trial of 100-300 μm versus 300-500 μm versus 100- to 300-μm + 300- to 500-μm Embospheres. (Abstract)

Prostatic Artery Embolization for Benign Prostatic Hyperplasia: Prospective Randomized Trial of 100-300 μm versus 300-500 μm versus 100- to 300-μm + 300- to 500-μm Embospheres. This study compared the safety and efficacy of prostatic arterial embolization (PAE) with that of trisacryl gelatin microspheres of different sizes for treatment of benign prostatic hyperplasia (BPH).This study consisted of a single-center, randomized controlled clinical trial in 138 patients who underwent PAE (...) for BPH between July 2015 and December 2016. Patients were randomized to PAE using microspheres of different sizes: group A patients were treated with microspheres 100-300 μm, group B with 300-500 μm, and group C with 100-300 μm followed by 300-500 μm. All patients were evaluated before and at 1, 3, 6, 12, and 18 months after PAE. Baseline data were comparable across the 3 groups, using the following mean International Prostate Symptom Score/quality of life (IPSS/QoL); prostate volume (PV) scores

2019 Journal of vascular and interventional radiology : JVIR Controlled trial quality: uncertain

96. Aconiti Lateralis Radix Preparata, the Dried Root of <i>Aconitum carmichaelii</i> Debx., Improves Benign Prostatic Hyperplasia via Suppressing 5-Alpha Reductase and Inducing Prostate Cell Apoptosis. (Full text)

Aconiti Lateralis Radix Preparata, the Dried Root of Aconitum carmichaelii Debx., Improves Benign Prostatic Hyperplasia via Suppressing 5-Alpha Reductase and Inducing Prostate Cell Apoptosis. Benign prostatic hyperplasia (BPH) is a common disease in elderly men which can be characterized by an abnormal enlargement of the prostate associated with lower urinary symptoms. Current medications available for BPH treatment display several adverse effects; thus, the search for effective (...) treatments with less side effects is still ongoing. In this study, we investigated the effect of Aconiti Lateralis Radix Preparata (dried root of Aconitum carmichaelii Debx.; AL), which is an herb used to treat extremely cold symptoms in traditional Korean medicine, on BPH using a testosterone propionate- (TP-) induced BPH rat model. Eight-week inguinal injection of TP induced BPH in rats, the prostate of which was displaying an abnormal proliferation. The pathological proliferation of the prostate

2019 Evidence-based Complementary and Alternative Medicine (eCAM) PubMed abstract

97. 1470 nm Diode Laser Enucleation vs Plasmakinetic Resection of the Prostate for Benign Prostatic Hyperplasia: A Randomized Study. (Full text)

1470 nm Diode Laser Enucleation vs Plasmakinetic Resection of the Prostate for Benign Prostatic Hyperplasia: A Randomized Study. The purpose of the current work was to comparatively assess 1470 nm diode laser enucleation of the prostate (DiLEP) and plasmakinetic resection of the prostate (PKRP) for treating benign prostatic hyperplasia (BPH).From January 2016 to March 2017, 157 individuals with bladder outflow obstruction caused by BPH were randomized to DiLEP and PKRP groups, for prospective (...) decrease was markedly less pronounced after DiLEP (P = 0.004). However, no patients needed blood transfusion in either group. The decrease in sodium level showed no marked differences between the DiLEP and PKRP groups (P = 0.380). In addition, complications were comparable and no significant differences in both groups. At 3, 6, and 12 months, International Prostate Symptom Score (IPSS), quality of life (QoL), maximum flow rate (Qmax), and postvoid residual (PVR) were similar in both groups (P > 0.05

2019 Journal of Endourology Controlled trial quality: uncertain PubMed abstract

98. Monopolar enucleation versus transurethral resection of the prostate for small- and medium-sized (&lt; 80 cc) benign prostate hyperplasia: a prospective analysis. (Abstract)

Monopolar enucleation versus transurethral resection of the prostate for small- and medium-sized (< 80 cc) benign prostate hyperplasia: a prospective analysis. To assess efficacy and safety of monopolar enucleation of the prostate (MEP) and to compare it with the current treatment standard for medium-sized prostates, < 80 cc, transurethral resection of the prostate (TURP).A prospective analysis patients undergoing a surgical procedure for their diagnosis of BPH (benign prostatic hyperplasia (...) was 1.7 and 3.2 days for TURP (p < 0.001). Hospital stay for MEP was 3.2 days vs. 4.8 days for TURP (p < 0.001). Both techniques shown comparable efficiency in benign prostatic obstruction relief with IPSS drop in MEP from 23.1 to 5.9 and in TURP group from 22.8 to 7.3, whereas Qmax increased from 8.2 to 20.5 after MEP and from 8.3 and 19.9 after TURP. Urinary incontinence rate after catheter removal in TURP group was 9.0% and 7.8% in MEP group, at 1 year follow-up, it was 1.4% and 3.1% in MEP

2019 World journal of urology

99. Efficacy and safety of enucleation vs. resection of prostate for treatment of benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. (Abstract)

Efficacy and safety of enucleation vs. resection of prostate for treatment of benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. The purpose of this study is to compare the efficacy and safety of transurethral enucleation and resection of prostate for treatment of benign prostatic hyperplasia (BPH).This meta-analysis was conducted through a systematic search before 1 September 2018. All included publications were randomized controlled trials (RCTs). Efficacy (...) was evaluated based on International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), and quality of life (QoL). Perioperative data and complications postoperatively were also assessed. The quality assessment of included studies and results was performed by using the Cochrane System and GRADE (grading of recommendation assessment, development, and evaluation) System.Thirty-one publications involving 26 RCTs with 3283 patients were assessed in this review. The differences between enucleation

2019 Prostate cancer and prostatic diseases

100. Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms. (Full text)

Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms. Benign prostatic hyperplasia (BPH) is an age-related disease, affecting a majority of elderly men worldwide. Medical management of BPH is an alternative to surgical treatment of this disease. Currently, α1-adrenergic receptor (α1-AR) antagonists are among the first line drugs to treat BPH by reducing the tension of urinary track and thus the obstructive symptoms

2018 PLoS ONE PubMed abstract

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>